Inclusion Criteria:

          -  Malignancies that are refractory to or intolerant of established therapies known to
             provide clinical benefit for the malignancy in question, or in the opinion of the
             Investigator, not be a candidate for such therapies

          -  Subjects must have recovered from the effects of any prior investigational system
             therapies

          -  For subjects with lymphoma with CNS involvement: must have relapsed or refractory CNS
             lymphoma, adequate bone marrow reserves and at least one lesion measurable for
             response using IPCG or Lugano criteria.

          -  For subjects with recurrent high-grade glioma or GBM, must have biopsy proven evidence
             (WHO Grade III or IV) and received external bean fractionated radiotherapy and at
             least 2 cycles of adjuvant temozolomide chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1

          -  Adequate organ function (bone marrow, hepatic, renal, cardiovascular)

          -  Female subjects of childbearing potential must have a negative pregnancy test within 7
             days of the start of treatment and must agree to use an effective method of
             contraception during the trial

        Exclusion Criteria:

          -  Untreated concurrent malignancies or malignancies that have been in complete remission
             for less than one year

          -  Treatment with strong inhibitors of CYP3A4 for which there are no therapeutic
             substitutions

          -  Inflammatory disorders of the gastrointestinal tract, or subjects with GI
             malabsorption

          -  HIV positive; known active hepatitis B or C

          -  Known hypersensitivity to any of the components of PRT811